Research progress of antibody-drug conjugates in the treatment of urothelial carcinoma
10.3969/j.issn.1671-8348.2025.07.030
- VernacularTitle:抗体偶联药物治疗尿路上皮癌的研究进展
- Author:
Feiyu YIN
1
;
Yu BAI
Author Information
1. 云南省肿瘤医院泌尿外科,昆明 650118
- Keywords:
antibody-drug conjugate;
urothelial carcinoma;
treatment;
targeted therapy
- From:
Chongqing Medicine
2025;54(7):1703-1708
- CountryChina
- Language:Chinese
-
Abstract:
Patients with locally advanced or metastatic urothelial carcinoma(LA/mUC)often develop resistance after platinum-based chemotherapy.In recent years,with the discovery of different biomarkers in UC cells and the continuous emergence of various antibody-drug conjugates(ADCs),treatment opportunities have emerged for LA/mUC patients who have progressed after platinum-based chemotherapy and immuno-therapy.Currently,Enfortumab vedotin(EV),Disitamab vedotin(RC48),and Sacituzumab govitecan(SG)have been approved by the US Food and Drug Administration(FDA)or China's National Medical Products Administration(NMPA).This article reviews research progress of ADCs in UC treatment to explore their ap-plication value for UC patients.
